비뇨병리연구회공청회 조남훈 연세대학교병리학교실
|
|
- Felicia Reynolds
- 5 years ago
- Views:
Transcription
1 비뇨병리연구회공청회 조남훈 연세대학교병리학교실
2 종양분류코드 - 방광암 표재성방광암 근층비침윤암 (Ta, Tis/ T1) 종양분류코드 진단서 ICD vs. ICO 사보험지급기준 중증질환분류 암등록사업 공보험 80-90% 지급기준 0 기암 -pta, ptis 특이한유형 면역 / 항암치료필요 재발과병기진행 다발성여부 진단확정주체 병리진단서 임상소견서 의무기록사
3 종양분류코드의변천사 Tumor coding SNOP/CAP ( 미국병리학자협의회 )/ACS 1967 ICD-8/WHO 형태학적 code+ 해부학적 code MONTAC/ACS/IARC ICD 에종양편삽입 (ICD-9) 1976 ICD-O 1975 ICD-9/WHO chapter II Neoplasm 1977 SNOMED/CAP 1990 ICD-O 2 nd 해부학적 code(c00-c80)+ 형태학적 code 1992 ICD-10/WHO chapter II Neoplasm 1993 SNOMED III/CAP 2000 ICD-O 3 rd / WHO 2000 SNOMED RT/CAP MONTAC: manual of tumor nomenclature and coding SNOP: systematized nomenclature of pathology SNOMED: systematized nomenclature of medicine CAP: College of American Pathologists ACS: American cancer society ICD: International statistical classification of disease, injuries and cause of death IARC: International agency for research on cancer
4 ICD-10 vs. ICD-O ICD C XY (site).z (subsite): Anatomy C67.9 (urinary bl) C68.9 (urinary system) ICD-O M-abcd (cell type)/0,1,2,3 (behavior) 1,2,3 (grade): Pathology M-8130/3 (papillary Uca) M-8130/2 (Pca, non-invasive) M-8120/2 (UCIS) 실제 Anatomy,Pathology C67.9, M-8130/3 ICD-O C67.9, M-8130/2 Malignant metastatic In situ benign Uncertain malignant ICD Neoplasm C80 C80 D09.9 D36.9 D48.9 UB C67.9 C79.1 D09.0 D30.3 D41.4 ICD-O UB M8130/3 M8130/6 M8130/2 M8130/0 M8130/1 M8145/3 (AC)
5 Confusing point in Naming-I 진단서의코드경우대부분 ICD 만사용 ICD-O 경우도해부학적구분이필요하므로 ICD code 를표기한다. 이표기는단지해부학적표시에불과하며 ICD 본래의악성과양성을구분하는기준과는다른개념이다. C67.9, M-8130/3 : urinary bladder papillary urothelial carcinoma, invasive C67.9, M-8130/2: urinary bladder papillary urothelial carcinoma, non-invasive C67.9, M-8120/2: urinary bladder urothelial carcinoma in situ
6 Confusing point in Naming-II ICD ICD-O pt Papillary UC, invasive C67.9 C67.9, M-8130/3 pt1+ Papillary UC, noninvasive D09.0 >C67.9 C67.9, M-8130/2 pta UC in situ D09.0 >C67.9 C67.9, M-8120/2 ptis Papillary Urothelial neoplasm, low malignant potential D41.4 or D09.0 >C67.9 C67.9, M-8120/1 In case of uncertain invasion: only papillary mass-commonly found: D09.0 questionable LP invasion ( /2; D09.0) In case of uncertain malignancy (LMP) D41.4
7 Issues to be issued 1. ICD vs. ICD-O 용어의혼동 2. TUR bladder (bx) 진단의대표성 Invasiveness 불분명의경우 Deep biopsy 유무 Multiplicity 무시 Grading 비고려 3. 타암종과의임상적차이 0 기암의 2 유형존재 In Situ 의예후및치료특이성 4. 임상적예후일치여부 Recur Progression Multiplicity ICD 문제점 해부학적용어 vs. 신생물구분 임상의문제점 BX algorithm 부재 Subepithelial CT or Deep muscle biopsy 여부 Stomach/colon EMR Excision Conization Case-sensitive issue 보험사문제점 ICD & ICD-O 요구 임상과병리의이견시임상우선 Case-sensitive issue 병리의문제점 Muscle 아닌경우 Bx 에서침윤여부파악어려움 Thermal Artifact Gray zone 해결필요
8 Meta-analysis of pta UC Materials and Methods: 2007-present for original article, review article for pta blader cancer and recurrence via PubMed, Cochrane, Google, EMBASE, SCOPUS. No language or geographic restriction Full paper reviewed 226 papers 130 papers with exclusion of clinical trial 10 papers with high priority Results Meta-analysis for recurrence in pta 30.5% (151 cases recurred / total 495 cases) Meta-analysis for progression in pta 3.4% (2 per 59 cases)
9 Recommendations for the diagnosis of non muscle-invasive bladder cancer Recommendations The renal and bladder US may be used during initial workup in patients with haematuria. GR C At the time of initial diagnosis of bladder cancer, CT urography or IVU should be performed only in selected cases (eg, tumours located in the t rigone). Cystoscopy is recommended in all patients with symptoms suggestive of bladder cancer. It cannot be replaced by cytology or by any ot her noninvasive test. Cystoscopy should describe all macroscopic features of the tumour (site, size, number, and appearance) and mucosal abnormalities. A bladder d iagram is recommended. Voided urine cytology or urinary markers are advocated to predict high-grade tumour before TUR. It is recommended to perform TUR in one piece for small papillary tumours (<1 cm), including part of the underlying bladder wall. It is recommended to perform TUR in fractions (including muscle tissue) for tumours >1 cm in diameter. It is recommended to take biopsies from abnormal-looking urothelium. Biopsies from normal-looking mucosa (trigone, bladder dome, and from right, left, anterior, and posterior bladder walls) are recommended only when cytology is positive or when exophytic tumour has a nonpapillary appearance. B A C C B B C Biopsy of the prostatic urethra is recommended for cases of bladder neck tumour, when bladder CIS is present or suspected, when there is posi tive cytology without evidence of tumour in the bladder, or when abnormalities of prostatic urethra are visible. If biopsy is not performed durin g the initial procedure, it should be completed at the time of the second resection. The biopsy should be taken from the precollicular area betw een 5 and 7 o clock positions using a resection loop. C If equipment is available, fluorescence-guided biopsy when bladder CIS is suspected (eg, positive cytology, recurrent tumour with previous histo ry of a high-grade lesion. B A second TUR should be performed 2 6 wk after the initial resection when the latter is incomplete (in large and multiple tumours, no muscle in the specimen) or when an exophytic high-grade and/or T1 tumour is detected. A The pathologic report should specify the grade, the depth of tumour invasion, and whether the lamina propria and muscle are present i n the specimen. Eur Urol 2011, 59:997 A
10 Weighting used to calculate recurrence and progression scores Factor Recurrence Progression No. of tumours Single Tumour diameter <3 cm cm 3 3 Prior recurrence rate Primary recurrence per year 2 2 >1 recurrence per year 4 2 Category Ta 0 0 T1 1 4 Concomitant CIS No 0 0 Yes 1 6 Grade (1973 WHO) G1 0 0 G2 1 0 G3 2 5 Total score
11 Prob. of recurrence/progression ac/to total score Recurrence score Probability of recurrence at 1 yr Probability of recurrence at 5 yr Recurrence risk group % (95% CI) % (95% CI) 0 15 (10 19) 31 (24 37) Low risk (21 26) 46 (42 49) Intermediate risk (35 41) 62 (58 65) (55 67) 78 (73 84) High risk Progression score Probability of progression at 1 yr Probability of progression at 5 yr Progression risk group % (95% CI) % (95% CI) (0 0.7) 0.8 (0 1.7) Low risk ( ) 6 (5 8) Intermediate risk (4 7) 17 (14 20) High risk (10 24) 45 (35 55)
12 Summary of Results in Metaanalysis -High risk pta/ptis- 1. Multiplicity in all 2. >3cm in size in almost all 3. Grade 3 in almost all 4. Outcome of initial cystoscopy
13 Further issues-minor Inverted papilloma Inverted papilloma 8120/0 Sinonasal inverted papilloma 8121/1 Testis nodule Pick cell adenoma 8640/1 Sertoli cell adenoma 8640/1
14 One example in code-remodelling by KPS-GIT Colon Low grade dysplasia ( 대부분 ICO/1) High grade dysplasia ( 대부분 ICO/2) Adenoca, in situ ( 대부분 ICO/2) Adenocarcinoma intramucosal ( 대부분 ICO/2) Adenoca, SM invasion (ICO/3) Appendix carcinoid (/3) <1cm, no invasion (/1) Any size, invasion (/3) Pancreas islet cell tumor (/0) Well diff (/1) Poor diff (/3) KPS-GIT only by questionarre No meta 분석 Comparative cases in other sys Cervix CIN I (ICO/0) CIN II (ICO/0) CIN III (ICO/2) CIS (ICO/2) Invasive SCC (ICO/3) PIN (8148/2) Ovary borderline tumor (/1) psuedomyxoma perotonei (/3) Struma ovari/carcinoid (/1) Granulosa cell tm (/1) malignant GCT (/3) Paraganglioma (/1) malignant (/3) Breast intraductal papillary ca-noninvasive (/2)
15 Ideal Goal to Discussion Looking for the most fair and appropriate decision For reasonable theory, not for just patients or clinicians For aligned outcome, not for deviated scope Remembering always, without exception, based on Pathology For final ruler or last judgment absolutely based on the current findings
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationThe pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationBladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)
Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationA215- Urinary bladder cancer tissues
A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationBladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist
Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential
More informationFINALIZED SEER SINQ QUESTIONS April July, 2017
20170040 Source 1: 2016 SEER Manual pgs: 91 Source 2: 2007 MP/H Rules Notes: Lung MP/H Rules/Histology--Lung: What is the histology code for lung cancer case identified pathologically from a metastatic
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationCOLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING
COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING COLON AND RECTUM SOLID TUMOR RULES Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent Terms Terms that are NOT Equivalent
More informationUpdates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
More information5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.
Common Differential Diagnoses in Urological Pathology Jonathan I. Epstein Prostate Adenocarcinoma vs. Urothelial Carcinoma 1 2 NKX3.1 NKX3.1 3 4 5 6 Proposed ISUP Recommendations Option to use PSA as a
More informationMultiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationUpdate on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual Rajal B. Shah, M.D. Director, Urologic Pathology SHAHR6@ccf.org @rajalbshah
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More informationJesse K. McKenney, MD
Jesse K. McKenney, MD Outline Microscopic anatomy of the urinary bladder Diagnosing invasion Subtle patterns (variants) of carcinoma Clinically important variants of carcinoma Microanatomy of Bladder Initial
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationColon and Rectum: 2018 Solid Tumor Rules
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Colon and Rectum: 2018 Solid Tumor Rules 1 Colon and Rectum Solid Tumor Rules Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationImmunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More informationPathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)
Pathologic Assessment of Invasion in TUR Specimens A. Lopez-Beltran T1 (ct1) 1 Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017 ESSENTIAL: Grade T stage CIS Number of lesions
More informationNeoplasms of the Prostate and Bladder
Neoplasms of the Prostate and Bladder 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 CDC & Florida DOH Attribution
More informationUrological Tumours 1 Kidney tumours 2 Bladder tumours
Urological Tumours 1 Kidney tumours 2 Bladder tumours Tim Bracey SpR Histopathology Derriford Hospital Kidney tumours What are we going to talk about?! Anatomy of urinary tract! Types of kidney tumours!
More informationKidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Head and Neck Tumours Pages 20, p27, p34, p38, p41, and p49 ly pn2a Metastasis in a single ipsilateral lymph node, less than 3cm in greatest dimension with
More information2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.
Slide 1 2007 New Data Items Data Due in: Days In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules. Slide 2 5 New Data Items Ambiguous Terminology
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationClassification of Neoplasms
Classification of Neoplasms ICD-10 Chapter 2, Neoplasms Codes C00-D48 Notes at beginning of Chapter 2 Classified by behaviour and site Correct use of Alphabetic index required Main terms Modifiers Table
More informationKentucky Cancer Registry Spring Training 2017
Kentucky Cancer Registry Spring Training 2017 What we will cover Coding instructions for grade Case examples addressing some areas of confusion for grade New grade data items coming in 2018 TNM Where to
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationApplication of Urovision FISH testing for diagnosis of bladder cancer
Application of Urovision FISH testing for diagnosis of bladder cancer Eva M. Wojcik, MD Chair and Professor of Pathology and Urology Loyola University, Chicago, USA Bladder cancer - current status ~ 76,900
More informationAfterword: The Paris System for Reporting Urinary Cytology
Afterword: The Paris System for Reporting Urinary Cytology Dorothy L. Rosenthal, Eva M. Wojcik, and Daniel F.I. Kurtycz The primary goal of The Paris System Working Group was standardizing the terminology
More informationExercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationMEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationDefinition of Synoptic Reporting
Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are
More informationFormat Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
More informationGenitourinary Neoplasms Updated for 2012 Requirements and CSv02.04
Presentation Outline Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04 X:\FCDS_PUB\wwwroot\downloads\Teleconfere nces\2013 FCDS Educational Webcast Series February 28, 2013 General Information
More informationGenitourinary Neoplasms Updated for 2012 Requirements and CSv02.04
Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04 X:\FCDS_PUB\wwwroot\downloads\Teleconfere nces\2013 FCDS Educational Webcast Series February 28, 2013 1 Steven Peace, BS, CTR Susan Smith
More information2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington
More informationYou Want ME to Stage that Case???
You Want ME to Stage that Case??? Jayne Holubowsky, CTR, Director, Virginia Cancer Registry 2 nd DelMarVa-DC Regional Conference October 11, 2018 What s New in the AJCC 8 th Edition Objectives Explain
More informationMale genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.
Male genital tract tumors Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital. adenocarcinoma Prostate Cancer most common male cancer in western countries more detected in
More informationQuestion: If in a particular case, there is doubt about the correct T, N or M category, what do you do?
Exercise 1 Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do? : 1. I mention both categories that are in consideration, e.g. pt1-2 2. I classify as
More information6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).
GU Cancer Staging: Updates and Challenging Areas 13 th Current Issues in Surgical Pathology San Francisco, CA June 5, 2010 Jeffry P. Simko, PhD, MD Associate Professor Departments of Urology and Anatomic
More informationMajor Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging
AJCC 8 th Edition Staging Major Rule Changes Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving patient
More informationKyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System
Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data
More information2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Eight Groups are Revised for 2018 Head & Neck Colon (includes rectosigmoid and rectum for cases diagnosed 1/1/2018 forward) Lung (2018 Draft not yet
More informationTake Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles
More informationTOPICS FOR DISCUSSION
INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los
More informationOutline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer
Concepts in Prostate Pathology Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Outline (1) Peculiarities of prostate cancer Peculiarities of prostate needle biopsy Needle bx vs. TURP Prostate
More informationIndex 179. Genital tract contaminants, 17, 20, 22, 150 papilloma virus-infected cells, 47 squamous cells, sources of, 7
Index Accuracy of urinary cytology, 166 Acute inflammatory cells, 38 catheter sample, 39 herpes simplex infections, 44 carcinomas, 104, 105 non-viral inclusions, 52, 53 voided urine, 17 Adenocarcinoma
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationBladder Case # 1. Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia.
DISCHARGE SUMMARY Bladder Case # 1 Date: 04/22/2010 Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia. Hospital Course: Mr.
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationSymptoms, Diagnosis and Classification
Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour
More informationFINALIZED SEER SINQ QUESTIONS
0066 Source 1: 2016 SEER Manual pgs: 78 Notes: Primary Site Primary Site/Corpus uteri: Is the primary site C541 (endometrium) or C543 (uterine fundus) when the histology states endometrial adenocarcinoma,
More informationEVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013
EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 Head and Neck Coding and Staging Head and Neck Coding and Staging Anatomy & Primary Site Sequencing and MPH
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationUterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationRationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm
Rationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm Eva M. Wojcik, MD Professor and Chair of Pathology Professor of Urology Loyola University, Chicago, Il Why to standardize
More informationCitation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma.
UvA-DARE (Digital Academic Repository) Advancements in diagnostic imaging for urothelial carcinoma Cauberg, E.C.C. Link to publication Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationIMAGING OF UPPER UT TCC
IMAGING OF UPPER UT TCC IS THERE AN EVIDENCE BASED STRATEGY? S A MOUSSA FRCS Ed, FRCR WESTERN GENERAL HOSPITAL EDINBURGH UPPER TRACT TCC 0.7-4% of patients with primary bladder cancer develops UT-TCC.
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Urethra and Periurethral Glands
Protocol for the Examination of Specimens From Patients With Carcinoma of the Urethra and Periurethral Glands Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition,
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationThe Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin
The Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin 24.06.15 Norman Barrett Smiles [A brief digression - Chair becoming
More informationSmall Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition
Small Intestine Protocol applies to all invasive carcinomas of the small intestine, including those with focal endocrine differentiation. Excludes carcinoid tumors, lymphomas, and stromal tumors (sarcomas).
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationUrology An introduction to cut up DR J R GOEPEL
Urology An introduction to cut up DR J R GOEPEL Overview Principles Individual organs Small pieces Partial resections Whole organs Data recording and data sets Principles You are working for the patient
More information6 UROLOGICAL CANCERS. 6.1 Key Points
6 UROLOGICAL CANCERS 6.1 Key Points Prostate Cancer Commonest cancer in males in Scotland Approximately 99% of cases occur in men aged > 50 years About 40% of cases present in men aged < 70 years when
More informationACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
More informationBLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR
Med. J. Malaysia Vol. 38. No. I March 1983. BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR ZAKRIYA MAHAMOOTH HUSSAIN AWANG SUMMARY
More informationBladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope
Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder
More information